Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Fig. 1

a Study design. Note: For patients not entering the OLTP, the safety follow-up visit occurred 12 weeks after the last dose of the DBTP. In the selected countries or regions, patients completing the DBTP on the study drug were eligible to participate in the OLTP (until launch of erenumab in the respective country or region). The study was powered only for the primary endpoint assessed in the overall population with an alpha level of 0.05. The endpoints were assessed as change from baseline over the last 4 weeks of the DBTP. * Duration of baseline was up to 35 days (5 weeks) due to COVID-19, with the last 28 days of this period considered for the assessment of headache frequency (MMD). DBTP, double-blind treatment phase; OLTP, open-label treatment phase; QM, once monthly; SC, subcutaneous. b Patient disposition in the DBTP. Note: *A patient is defined as a completer for the DBT if the individual had received the Week 8 dose (erenumab or placebo). † A patient is defined as completer for the DBTP, if the individual had completed all scheduled visits in the DBTP, including Week 12 visit, or entered in the OLTP. For patients who continued to OLTP, the cut-off was end of treatment. For patients who entered into the safety follow-up after double-blind treatment, the cut-off is 11-Aug-2021 or end of study whichever is the earliest. Screened were those patients who had signed an informed consent form. Full analysis set comprised all randomised patients. DBT, double-blind treatment; DBTP, double-blind treatment phase; OLTP, open-label treatment phase

Back to article page